T. Rowe Price Associates
JUNO

T. Rowe Price Associates’s Juno Therapeutics, Inc. JUNO Stock Holding History

T. Rowe Price Associates’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,095,263
Closed -$50.1M – 2623
2017
Q4 		$50.1M Sell
1,095,263
-35,542
-3% -$1.77M 0.01% 865
2017
Q3 		$50.7M Buy
1,130,805
+370,583
+49% +$12.6M 0.01% 847
2017
Q2 		$22.7M Sell
760,222
-8,490
-1% -$209K ﹤0.01% 1125
2017
Q1 		$17.1M Sell
768,712
-42,006
-5% -$901K ﹤0.01% 1221
2016
Q4 		$15.3M Buy
810,718
+787,020
+3,321% +$19.3M ﹤0.01% 1220
2016
Q3 		$711K Buy
23,698
+98
+0.4% +$3.05K ﹤0.01% 1881
2016
Q2 		$907K Sell
23,600
-166,829
-88% -$6.92M ﹤0.01% 1742
2016
Q1 		$7.25M Buy
190,429
+123,500
+185% +$4.3M ﹤0.01% 1332
2015
Q4 		$2.94M Sell
66,929
-30,877
-32% -$1.53M ﹤0.01% 1485
2015
Q3 		$3.98M Sell
97,806
-294
-0.3% -$12.9K ﹤0.01% 1470
2015
Q2 		$5.23M Buy
+98,100
New +$5.21M ﹤0.01% 1472

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

T. Rowe Price Associates's JUNO Position: Q1 2018 in Review

T. Rowe Price Associates sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 1,095,263 shares — an estimated $50.1M sold.

T. Rowe Price Associates first reported a position in JUNO in Q2 2015 and held it in 11 quarters. The position peaked at $50.7M in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • T. Rowe Price Associates reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,095,263 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $50.1M.
  • T. Rowe Price Associates first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 11 quarters.
  • T. Rowe Price Associates's Juno Therapeutics, Inc. position peaked at $50.7M in Q3 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on T. Rowe Price Associates's 13F filing for Q1 2018, filed 14 May 2018.